Joint position statement on “Nutraceuticals for the treatment of hypercholesterolemia” of the Italian Society of Diabetology (SID) and of the Italian Society for the Study of Arteriosclerosis (SISA)

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 27, Issue 1, 2017, Pages 2-17

  Pirro, M ^a,b   Vetrani, C ^c,d   Bianchi, C ^d,e   Mannarino, M R ^a,b   Bernini, F ^b,f   Rivellese, A A ^c,d  

^a UNIVERSITY OF PERUGIA   (Italy)

^b Italian Society for the Study of Arteriosclerosis (SISA)   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d Italian Society of Diabetology (SID)   (Italy)

^e UNIVERSITY HOSPITAL OF PISA   (Italy)

^f UNIVERSITY OF PARMA   (Italy)

Author keywords

Berberine; Cholesterol; Fiber; Nutraceuticals; Phytosterols; Policosanol; Red yeast rice; Soy

Indexed keywords

BERBERINE; BETA GLUCAN; CHITOSAN; CHOLESTIN; GUAR GUM; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; ISPAGULA; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MANNAN; NUTRACEUTICAL; PECTIN; PHYTOSTEROL; PLACEBO; POLICOSANOL; BIOLOGICAL MARKER;

CARDIOVASCULAR RISK; DIETARY FIBER; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; JOINT; LIPID BLOOD LEVEL; META ANALYSIS (TOPIC); POSITION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SOYBEAN; ADVERSE EFFECTS; BLOOD; CONSENSUS; DIETARY SUPPLEMENT; DOWN REGULATION; PATIENT SELECTION; PRACTICE GUIDELINE; RISK FACTOR; TREATMENT OUTCOME;

BIOMARKERS; CHOLESTEROL, LDL; CONSENSUS; DIETARY SUPPLEMENTS; DOWN-REGULATION; HUMANS; HYPERCHOLESTEROLEMIA; PATIENT SELECTION; RISK FACTORS; TREATMENT OUTCOME;

EID: 85008210389     PISSN: 09394753     EISSN: 15903729     Source Type: Journal    
DOI: 10.1016/j.numecd.2016.11.122     Document Type: Review

References (153)

1. [1] Catapano, A.L., Graham, I., De Backer, G., Wiklund, O., Chapman, M.J., Drexel, H., et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis, 2016, 1–64.
2. [2] Stamler, J., Wentworth, D., Neaton, J.D., Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the multiple risk factor intervention trial (MRFIT). JAMA 256 (1986), 2823–2828.
3. [3] Castelli, W.P., Cholesterol and lipids in the risk of coronary artery disease–the Framingham Heart Study. Can J Cardiol 4:Suppl. A (1988), 5A–10A.
4. [4] Naci, H., Brugts, J.J., Fleurence, R., Tsoi, B., Toor, H., Ades, A.E., Comparative benefits of statins in the primary and secondary prevention of major coronary events and all-cause mortality: a network meta-analysis of placebo-controlled and active-comparator trials. Eur J Prev Cardiol 20 (2013), 641–657.
5. [5] Rembold, C.M., To statin or to non-statin in coronary disease–considering absolute risk is the answer. Atherosclerosis 195 (2007), 1–6.
6. [6] Bruckert, E., Ferrières, J., Evidence supporting primary prevention of cardiovascular diseases with statins: gaps between updated clinical results and actual practice. Arch Cardiovasc Dis 107 (2014), 188–200.
7. [7] Braamskamp, M.J., Hutten, B.A., Wiegman, A., Early initiation of statin treatment in children with familial hypercholesterolaemia. Curr Opin Lipidol 26 (2015), 236–239.
8. [8] Cholesterol Treatment Trialists’ (CTT) Collaboration, Fulcher, J., O'Connell, R., Voysey, M., Emberson, J., Blackwell, L., Mihaylova, B., et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet 385 (2015), 1397–1405.
9. [9] Cannon, C.P., Blazing, M.A., Giugliano, R.P., McCagg, A., White, J.A., Theroux, P., et al., IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 372 (2015), 2387–2397.
10. [10] Horton, J.D., Cohen, J.C., Hobbs, H.H., PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res 50:Suppl. (2009), S172–S177.
11. [11] Schulz, R., Schlüter, K.D., Laufs, U., Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9). Basic Res Cardiol, 110, 2015, 4.
12. [12] Smith, C.S., Cannon, C.P., McCabe, C.H., Murphy, S.A., Bentley, J., Braunwald, E., Early initiation of lipid-lowering therapy for acute coronary syndromes improves compliance with guideline recommendations: observations from the orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. Am Heart J 149 (2005), 444–450.
13. [13] Navarese, E.P., Kowalewski, M., Andreotti, F., van Wely, M., Camaro, C., Kolodziejczak, M., et al. Meta-analysis of time-related benefits of statin therapy in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Am J Cardiol 113 (2014), 1753–1764.
14. [14] Chapman, K., Can people make healthy changes to their diet and maintain them in the long term? A review of the evidence. Appetite 54 (2010), 433–441.
15. [15] McRorie, J.W. Jr., Evidence-based approach to fiber supplements and clinically meaningful health benefits, part 1: what to look for and how to recommend an effective fiber therapy. Nutr Today 50 (2015), 82–89.
16. [16] Chutkan, R., Fahey, G., Wright, W.L., McRorie, J., Viscous versus nonviscous soluble fiber supplements: mechanisms and evidence for fiber-specific health benefits. J Am Acad Nurse Pract 24 (2012), 476–487.
17. [17] Vuksan, V., Jenkins, A.L., Rogovik, A.L., Fairgrieve, C.D., Jovanovski, E., Leiter, L.A., Viscosity rather than quantity of dietary fibre predicts cholesterol-lowering effect in healthy individuals. Br J Nutr 106 (2011), 1349–1352.
18. [18] Assmann, G., Buono, P., Daniele, A., Della Valle, E., Farinaro, E., Ferns, G., et al. Functional foods and cardiometabolic diseases* International task Force for prevention of cardiometabolic diseases. Nutr Metab Cardiovasc Dis 24 (2014), 1272–1300.
19. [19] Yang, Y., Zhao, L.G., Wu, Q.J., Ma, X., Xiang, Y.B., Association between dietary fiber and lower risk of all-cause mortality: a meta-analysis of cohort studies. Am J Epidemiol 181 (2015), 83–91.
20. [20] Moreno Franco, B., León Latre, M., Andrés Esteban, E.M., Ordovás, J.M., Casasnovas, J.A., Peñalvo, J.L., Soluble and insoluble dietary fibre intake and risk factors for metabolic syndrome and cardiovascular disease in middle-aged adults: the AWHS cohort. Nutr Hosp 30 (2014), 1279–1288.
21. [21] Pereira, M.A., O'Reilly, E., Augustsson, K., Fraser, G.E., Goldbourt, U., Heitmann, B.L., et al. Dietary fiber and risk of coronary heart disease: a pooled analysis of cohort studies. Arch Intern Med 164 (2004), 370–376.
22. [22] Bazzano, L.A., Thompson, A.M., Tees, M.T., Nguyen, C.H., Winham, D.M., Non-soy legume consumption lowers cholesterol levels: a meta-analysis of randomized controlled trials. Nutr Metab Cardiovasc Dis 21 (2011), 94–103.
23. [23] Estruch, R., Martínez-González, M.A., Corella, D., Basora-Gallisá, J., Ruiz-Gutiérrez, V., Covas, M.I., et al., PREDIMED Study Investigators. Effects of dietary fibre intake on risk factors for cardiovascular disease in subjects at high risk. J Epidemiol Community Health 63 (2009), 582–588.
24. [24] Riccardi, G., Rivellese, A.A., Effects of dietary fiber and carbohydrate on glucose and lipoprotein metabolism in diabetic patients. Diabetes Care 14 (1991), 1115–1125.
25. [25] Grooms, K.N., Ommerborn, M.J., Pham do, Q., Djoussé, L., Clark, C.R., Dietary fiber intake and cardiometabolic risks among US adults, NHANES 1999–2010. Am J Med 126 (2013), 1059–1067.
26. [26] Sette, S., Le Donne, C., Piccinelli, R., Arcella, D., Turrini, A., Leclercq, C., INRAN-SCAI 2005-6 Study Group. The third Italian national food consumption survey, INRAN-SCAI 2005-06–part 1: nutrient intakes in Italy. Nutr Metab Cardiovasc Dis 21 (2011), 922–932.
27. [27] Cust, A.E., Skilton, M.R., van Bakel, M.M., Halkjaer, J., Olsen, A., Agnoli, C., et al. Total dietary carbohydrate, sugar, starch and fibre intakes in the European prospective investigation into cancer and nutrition. Eur J Clin Nutr 63 (2009), S37–S60.
28. [28] Brown, L., Rosner, B., Willett, W.W., Sacks, F.M., Cholesterol-lowering effects of dietary fiber: a meta-analysis. Am J Clin Nutr 69 (1999), 30–42.
29. [29] Whitehead, A., Beck, E.J., Tosh, S., Wolever, T.M., Cholesterol-lowering effects of oat β-glucan: a meta-analysis of randomized controlled trials. Am J Clin Nutr 100 (2014), 1413–1421.
30. [30] Wei, Z.H., Wang, H., Chen, X.Y., Wang, B.S., Rong, Z.X., Wang, B.S., et al. Time- and dose-dependent effect of psyllium on serum lipids in mild-to-moderate hypercholesterolemia: a meta-analysis of controlled clinical trials. Eur J Clin Nutr 63 (2009), 821–827.
31. [31] Solà, R., Bruckert, E., Valls, R.M., Narejos, S., Luque, X., Castro-Cabezas, M., et al. Soluble fibre (Plantago ovata husk) reduces plasma low-density lipoprotein (LDL) cholesterol, triglycerides, insulin, oxidised LDL and systolic blood pressure in hypercholesterolaemic patients: a randomised trial. Atherosclerosis 211 (2010), 630–637.
32. [32] Jull, A.B., Ni Mhurchu, C., Bennett, D.A., Dunshea-Mooij, C.A., Rodgers, A., Chitosan for overweight or obesity. Cochrane Database Syst Rev, 3, 2008, CD003892, 10.1002/14651858.CD003892.pub3.
33. [33] Sood, N., Baker, W.L., Coleman, C.I., Effect of glucomannan on plasma lipid and glucose concentrations, body weight, and blood pressure: systematic review and meta-analysis. Am J Clin Nutr 88 (2008), 1167–1175.
34. [34] Reppas, C., Swidan, S.Z., Tobey, S.W., Turowski, M., Dressman, J.B., Hydroxypropylmethylcellulose significantly lowers blood cholesterol in mildly hypercholesterolemic human subjects. Eur J Clin Nutr 63 (2009), 71–77.
35. [35] Maki, K.C., Carson, M.L., Miller, M.P., Anderson, W.H., Turowski, M., Reeves, M.S., et al. Hydroxypropylmethylcellulose lowers cholesterol in statin-treated men and women with primary hypercholesterolemia. Eur J Clin Nutr 63 (2009), 1001–1007.
36. [36] De Natale, C., Annuzzi, G., Bozzetto, L., Mazzarella, R., Costabile, G., Ciano, O., et al. Effects of a plant-based high-carbohydrate/high-fiber diet versus high-monounsaturated fat/low-carbohydrate diet on postprandial lipids in type 2 diabetic patients. Diabetes Care 32 (2009), 2168–2173.
37. [37] Giacco, R., Costabile, G., Della Pepa, G., Anniballi, G., Griffo, E., Mangione, A., et al. A whole-grain cereal-based diet lowers postprandial plasma insulin and triglyceride levels in individuals with metabolic syndrome. Nutr Metab Cardiovasc Dis 24 (2014), 837–844.
38. [38] EFSA Panel on Dietetic Products, Nutrition, and Allergies (NDA), Scientific opinion on dietary Reference values for carbohydrates and dietary fibre. EFSA J, 8, 2010, 10.2903/j.efsa.2010.1462 1462 [77 pp.]. Available online: www.efsa.europa.eu.
39. [39] Dahl, W.J., Stewart, M.L., Position of the academy of nutrition and dietetics: health implications of dietary fiber. J Acad Nutr Diet 115 (2015), 1861–1870.
40. [40] Gylling, H., Plat, J., Turley, S., Ginsberg, H.N., Ellegård, L., Jessup, W., et al., European Atherosclerosis Society Consensus Panel on Phytosterols. Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease. Atherosclerosis 232 (2014), 346–360.
41. [41] Chen, Z.Y., Ma, K.Y., Liang, Y., Peng, C., Zuo, Y., Role and classification of cholesterol-lowering functional foods. J Funct Foods 3 (2011), 61–69.
42. [42] Andersson, S.W., Skinner, J., Ellegård, L., Welch, A.A., Bingham, S., Mulligan, A., et al. Intake of dietary plant sterols is inversely related to serum cholesterol concentration in men and women in the EPIC Norfolk population: a cross-sectional study. Eur J Clin Nutr 58 (2004), 1378–1385.
43. [43] Klingberg, S., Ellegård, L., Johansson, I., Hallmans, G., Weinehall, L., Andersson, H., et al. Inverse relation between dietary intake of naturally occurring plant sterols and serum cholesterol in northern Sweden. Am J Clin Nutr 87 (2008), 993–1001.
44. [44] Wang, P., Chen, Y.M., He, L.P., Chen, C.G., Zhang, B., Xue, W.Q., et al. Association of natural intake of dietary plant sterols with carotid intima-media thickness and blood lipids in Chinese adults: a cross-section study. PLoS One, 7, 2012, e32736.
45. [45] Mannarino, E., Pirro, M., Cortese, C., Lupattelli, G., Siepi, D., Mezzetti, A., et al. Effects of a phytosterol-enriched dairy product on lipids, sterols and 8-isoprostane in hypercholesterolemic patients: a multicenter Italian study. Nutr Metab Cardiovasc Dis 19 (2009 Feb), 84–90.
46. [46] Abumweis, S.S., Barake, R., Jones, P.J., Plant sterols/stanols as cholesterol lowering agents: a meta-analysis of randomized controlled trials. Food Nutr Res, 52, 2008.
47. [47] Wu, T., Fu, J., Yang, Y., Zhang, L., Han, J., The effects of phytosterols/stanols on blood lipid profiles: a systematic review with meta-analysis. Asia Pac J Clin Nutr 18 (2009), 179–186.
48. [48] Demonty, I., Ras, R.T., van der Knaap, H.C., Duchateau, G.S., Meijer, L., Zock, P.L., et al. Continuous dose-response relationship of the LDL-cholesterol-lowering effect of phytosterol intake. J Nutr 139 (2009), 271–284.
49. [49] Ras, R.T., Hiemstra, H., Lin, Y., Vermeer, M.A., Duchateau, G.S., Trautwein, E.A., Consumption of plant sterol-enriched foods and effects on plasma plant sterol concentrations–a meta-analysis of randomized controlled studies. Atherosclerosis 230 (2013), 336–346.
50. [50] Ras, R.T., Geleijnse, J.M., Trautwein, E.A., LDL-cholesterol-lowering effect of plant sterols and stanols across different dose ranges: a meta-analysis of randomised controlled studies. Br J Nutr 112 (2014), 214–219.
51. [51] Malhotra, A., Shafiq, N., Arora, A., Singh, M., Kumar, R., Malhotra, S., Dietary interventions (plant sterols, stanols, omega-3 fatty acids, soy protein and dietary fibers) for familial hypercholesterolaemia. Cochrane Database Syst Rev, 6, 2014, CD001918, 10.1002/14651858.CD001918.pub3.
52. [52] Baker, W.L., Baker, E.L., Coleman, C.I., The effect of plant sterols or stanols on lipid parameters in patients with type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract 84 (2009), e33–e37.
53. [53] Demonty, I., Ras, R.T., van der Knaap, H.C., Meijer, L., Zock, P.L., Geleijnse, J.M., et al. The effect of plant sterols on serum triglyceride concentrations is dependent on baseline concentrations: a pooled analysis of 12 randomised controlled trials. Eur J Nutr 52 (2013), 153–160.
54. [54] Ketomaki, A., Gylling, H., Miettinen, T.A., Effects of plant stanol and sterol esters on serum phytosterols in a family with familial hypercholesterolemia including a homozygous subject. J Lab Clin Med 143 (2004), 255–262.
55. [55] Musa-Veloso, K., Poon, T.H., Elliot, J.A., Chung, C., A comparison of the LDL-cholesterol lowering efficacy of plant stanols and plant sterols over a continuous dose range: results of a meta-analysis of randomized, placebo-controlled trials. Prostaglandins Leukot Essent Fatty Acids 85 (2011), 9–28.
56. [56] Lichtenstein, A.H., Deckelbaum, R.J., AHA Science Advisory. Stanol/sterol ester-containing foods and blood cholesterol levels. A statement for healthcare professionals from the nutrition committee of the council on nutrition, physical activity, and metabolism of the American Heart Association. Circulation 103 (2001), 1177–1179.
57. [57] Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Z., Verschuren, M., et al. European Association for Cardiovascular Prevention & Rehabilitation (EACPR), ESC Committee for Practice Guidelines (CPG). European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The fifth joint task force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 33 (2012), 1635–1701.
58. [58] IAS International Atherosclerosis Society. An international atherosclerosis society position paper: global recommendations for the management of dyslipidemia. Available online: http://www.athero.org/download/IASPPGuidelines_FullReport_20131011.pdf.
59. [59] Ajagbe, B.O., Othman, R.A., Myrie, S.B., Plant sterols, stanols, and sitosterolemia. J AOAC Int 98 (2015), 716–723.
60. [60] van Ee, J.H., Soy constituents: modes of action in low-density lipoprotein management. Nutr Rev 67:4 (2009), 222–234.
61. [61] Setchell, K.D.R., Phytoestrogens: the biochemistry, physiology, and implications for human health of soy isoflavones. Am J Clin Nutr 68 (1998), 1333S–1346S.
62. [62] Wang, H., Murphy, P.A., Isoflavone content in commercial soybean foods. J Agric Food Chem 42 (1994), 1666–1673.
63. [63] Descovich, G.C., Ceredi, C., Gaddi, A., Benassi, M.S., Mannino, G., Colombo, L., et al. Multicentre study of soybean protein diet for outpatient hyper-cholesterolaemic patients. Lancet 2 (1980), 709–712.
64. [64] Marlett, J.A., Sites and mechanism for the hypocholesterolemic actions of soluble dietary fiber sources. Adv Exp Med Biol 427 (1997), 109–121.
65. [65] Torres, N., Torre-Villalvazo, I., Tovar, A.R., Regulation of lipid metabolism by soy protein and its implication in diseases mediated by lipid disorders. J Nutr Biochem 17 (2006), 365–373.
66. [66] Sirtori, C.R., Galli, C., Anderson, J.W., Arnoldi, A., Nutritional and nutraceutical approaches to dyslipidemia and atherosclerosis prevention: focus on dietary proteins. Atherosclerosis 203 (2009), 8–17.
67. [67] Anderson, J.W., Johnstone, B.M., Cook-Newell, M.E., Meta-analysis of the effects of soy-protein intake on serum lipids. N Engl J Med 333 (1995), 276–282.
68. [68] U.S. Food and Drug Administration [Internet]. Silver Spring (MD): U.S. Food and Drug Administration; 2014. Code of Federal Regulations Title 21, vol. 2, Sec. 101.82 Health Claims: Soy protein and risk of coronary heart disease (CHD). 2014. [cited 2014 Oct 28]. Available from: http://www.fda.gov/default.htm.
69. [69] Weggemans, R.M., Trautwein, E.A., Relation between soy-associated isoflavones and LDL and HDL cholesterol concentrations in humans: a meta-analysis. Eur J Clin Nutr 57 (2003), 940–946.
70. [70] Zhuo, X.-G., Melby, M.K., Watanabe, S., Soy isoflavones intake lowers serum LDL cholesterol: a meta-analysis of 8 randomized controlled trials in humans. J Nutr 134 (2004), 2395–2400.
71. [71] Zhan, S., Ho, S.C., Meta-analysis of the effects of soy-protein containing isoflavones on the lipid profile. Am J Clin Nutr 81 (2005), 397–408.
72. [72] Reynolds, K., Chin, A., Lees, K.A., Kguyen, A., Bujnowski, D., He, J., A metaanalysis of the effect of soy protein supplementation on serum lipids. Am J Cardiol 98 (2006), 633–640.
73. [73] Taku, K., Umegaki, K., Sato, Y., Soy isoflavones lower serum total and LDL cholesterol in humans: a meta-analysis of 11 randomized controlled trials. Am J Clin Nutr 85 (2007), 1148–1156.
74. [74] Harland, J.I., Haffner, T.A., Systematic review, meta-analysis and regression of randomised controlled trials reporting an association between an intake of circa 25 g soya protein per day and blood cholesterol. Atherosclerosis 200 (2008), 13–27.
75. [75] Anderson, J.W., Bush, H.M., Soy protein effects on serum lipoproteins: a quality assessment and meta-analysis of randomized, controlled studies. J Am Coll Nutr 30 (2011), 79–91.
76. [76] Yang, B., Chen, Y., Xu, T., Yu, Y., Huang, T., Hu, X., et al. Systematic review and meta-analysis of soy products consumption in patients with type 2 diabetes mellitus. Asia Pac J Clin Nutr 20:4 (2011), 593–602.
77. [77] European Food Safety Authority, Scientific opinion on the substantiation of a health claim related to isolated soy protein and reduction of blood LDL-cholesterol concentrations pursuant to Article 14 of Regulation (EC) No 1924/2006. EFSA J, 10(2), 2012, 2555.
78. [78] Benkhedda, K., Boudrault, C., Sinclair, S.E., Marles, R.J., Xiao, C.W., Underhill, L., Health Canada's proposal to accept a health claim about soy products and cholesterol lowering. Int Food Risk Anal J 4 (2014), 1–12.
79. [79] Sacks, F.M., Lichtenstein, A., Van Horn, L., Harris, W., Kris-Etherton, P., Winston, M., Soy-protein, isoflavones, and cardiovascular health: an American Heart Association advisory panel for professionals from the nutrition committee. Circulation 113 (2006), 1034–1044.
80. [80] Girgih, A.T., Myrie, S.B., Aluko, R.E., Jones, P.J.H., Is category ‘A’ status assigned to soy-protein and coronary heart disease risk reduction health claim by the United States Food and Drug Administration still justifiable?. Trends Food Sci Technol 30 (2013), 121–132.
81. [81] Padhi, E.M., Blewett, H.J., Duncan, A.M., Guzman, R.P., Hawke, A., Seetharaman, K., et al. Whole soy flour incorporated into a muffin and consumed at 2 doses of soy protein does not lower LDL cholesterol in a randomized, double-blind controlled trial of hypercholesterolemic adults. J Nutr 145:12 (2015), 2665–2674.
82. [82] Gouni-Berthold, I., Berthold, H.K., Policosanol: clinical pharmacology and therapeutic significance of a new lipid-lowering agent. Am Heart J 143 (2002), 356–365.
83. [83] McCarty, M.F., Policosanol safely down-regulates HMG-CoA reductase—potential as a component of the Esselstyn regimen. Med Hypotheses 59 (2002), 268–279.
84. [84] Menéndez, R., Amor, A.M., Rodeiro, I., González, R.M., González, P.C., Alfonso, J.L., et al. Policosanol modulates HMGCoA reductase activity in cultured fibroblasts. Arch Med Res 32 (2001), 8–12.
85. [85] Noa, M., Mas, R., Mesa, R., A comparative study of policosanol vs lovastatin on intimal thickening in rabbit cuffed carotid artery. Pharmacol Res 43 (2001), 31–37.
86. [86] Castaño, G., Mas, R., Fernández, L., Illnait, J., Mesa, M., Alvarez, E., et al. Comparison of the efficacy and tolerability of policosanol with atorvastatin in elderly patients with type II hypercholesterolaemia. Drugs Aging 20 (2003), 153–163.
87. [87] Mas, R., Castaño, G., Fernández, J., Gamez, R., Illnait, J., Fernandez, L., et al. Long-term effects of policosanol on older patients with type 2 diabetes. Asia Pac J Clin Nutr, 13(Suppl.), 2004, S101.
88. [88] Head, K.A., (eds.) Policosanol monograph, vol. 9, 2004, Thorne Research Inc, Sandpoint, ID, 312–317.
89. [89] Castaño, G., Fernández, L., Mas, R., Illnait, J., Gámez, R., Mendoza, S., et al. Effects of addition of policosanol to omega-3 fatty acid therapy on the lipid profile of patients with type II hypercholesterolaemia. Drugs R D 6 (2005), 207–219.
90. [90] Mas, R., Castaño, G., Fernández, J., Gamez, R., Illnait, J., Fernandez, L., et al. Long-term effects of policosanol on obese patients with type II hypercholesterolemia. Asia Pac J Clin Nutr, 13(Suppl.), 2004, S102.
91. [91] Castaño, G., Menéndez, R., Más, R., Amor, A., Fernández, J.L., González, R.L., et al. Effects of policosanol and lovastatin on lipid profile and lipid peroxidation in patients with dyslipidemia associated with type 2 diabetes mellitus. Int J Clin Pharmacol Res 22 (2002), 89–99.
92. [92] Castano, G., Mas, R., Fernandez, J.C., Fernandez, L., Illnait, J., Lopez, E., Effects of policosanol on older patients with hypertension and type II hypercholesterolaemia. Drugs R D 3 (2002), 159–172.
93. [93] Castano, G., Mas, R., Fernandez, L., Illnait, J., Gamez, R., Alvarez, E., Effects of policosanol 20 versus 40 mg/day in the treatment of patients with type II hypercholesterolemia: a 6-month double-blind study. Int J Clin Pharmacol Res 21 (2001), 43–57.
94. [94] Castano, G., Mas, R., Fernandez, J.C., Illnait, J., Fernandez, L., Alvarez, E., Effects of policosanol in older patients with type II hypercholesterolemia and high coronary risk. J Gerontol A Biol Sci Med Sci 56 (2001), M186–M192.
95. [95] Menéndez, R., Más, R., Amor, A.M., González, R., Fernández, J.C., Rodeiro, I., Effects of policosanol treatment on the susceptibility of low density lipoprotein (LDL) isolated from healthy volunteers to oxidative modification in vitro. Br J Clin Pharmacol 50 (2000), 255–262.
96. [96] Castaño, G., Más, R., Fernández, L., Fernández, J.C., Illnait, J., López, L.E., et al. Effects of policosanol on postmenopausal women with type II hypercholesterolemia. Gynecol Endocrinol 14 (2000), 187–195.
97. [97] Mas, R., Castano, G., Illnait, J., Fernandez, L., Fernandez, J., Aleman, C., et al. Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors. Clin Pharmacol Ther 65 (1999), 439–447.
98. [98] Crespo, N., Illnait, J., Mas, R., Fernandez, L., Fernandez, J., Castano, G., Comparative study of the efficacy and tolerability of policosanol and lovastatin in patients with hypercholesterolemia and noninsulin dependent diabetes mellitus. Int J Clin Pharmacol Res 19 (1999), 117–127.
99. [99] Castaño, G., Más, R., Arruzazabala, M.L., Noa, M., Illnait, J., Fernández, J.C., et al. Effects of policosanol and pravastatin on lipid profile, platelet aggregation and endothelemia in older hypercholesterolemic patients. Int J Clin Pharmacol Res 19 (1999), 105–116.
100. [100] Varady, K.A., Wang, Y., Jones, P.J., Role of policosanols in the prevention and treatment of cardiovascular disease. Nutr Rev 61 (2003), 376–383.
101. [101] Chen, J.T., Wesley, R., Shamburek, R.D., Pucino, F., Csako, G., Meta-analysis of natural therapies for hyperlipidemia: plant sterols and stanols versus policosanol. Pharmacotherapy 25 (2005), 171–183.
102. [102] Greyling, A., De Witt, C., Oosthuizen, W., Jerling, J.C., Effects of a policosanol supplement on serum lipid concentrations in hypercholesterolaemic and heterozygous familial hypercholesterolaemic subjects. Br J Nutr 95 (2006), 968–975.
103. [103] Berthold, H.K., Unverdorben, S., Degenhardt, R., Bulitta, M., Gouni-Berthold, I., Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia: a randomized controlled trial. JAMA 295 (2006), 2262–2269.
104. [104] Lin, Y., Rudrum, M., van der Wielen, R.P., Trautwein, E.A., McNeill, G., Sierksma, A., et al. Wheat germ policosanol failed to lower plasma cholesterol in subjects with normal to mildly elevated cholesterol concentrations. Metabolism 53 (2004), 1309–1314.
105. [105] Dulin, M.F., Hatcher, L.F., Sasser, H.C., Barringer, T.A., Policosanol is ineffective in the treatment of hypercholesterolemia: a randomized controlled trial. Am J Clin Nutr 84 (2006), 1543–1548.
106. [106] European Food Safety Authority, Scientific opinion on the substantiation of health claims related to policosanols from sugar cane wax and maintenance of normal blood LDL-cholesterol concentrations (ID 1747, 1748, 1864, 1951, 1954, 4693) and maintenance of normal blood HDL-cholesterol concentrations (ID 1747, 1748, 1864, 1951, 1954, 4693) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA J, 9(6), 2011, 2255.
107. [107] Gordon, R.Y., Becker, D.J., The role of red yeast rice for the physician. Curr Atheroscler Rep 13 (2011), 73–80.
108. [108] Burke, F.M., Red yeast rice for the treatment of dyslipidemia. Curr Atheroscler Rep, 17, 2015 Apr, 495.
109. [109] Ma, J., Li, Y., Ye, Q., Li, J., Hua, Y., Ju, D., et al. Constituents of red yeast rice, a traditional Chinese food and medicine. J Agric Food Chem 48 (2000), 5220–5522.
110. [110] Mannarino, M.R., Ministrini, S., Pirro, M., Nutraceuticals for the treatment of hypercholesterolemia. Eur J Intern Med 25 (2014), 592–599.
111. [111] Heber, D., Yip, I., Ashley, J.M., Elashoff, D.A., Elashoff, R.M., Go, V.L., Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. Am J Clin Nutr 69 (1999), 231–236.
112. [112] Liu, J., Zhang, J., Shi, Y., Grimsgaard, S., Alraek, T., Fønnebø, V., Chinese red yeast rice (Monascus purpureus) for primary hyperlipidemia: a meta-analysis of randomized controlled trials. Chin Med, 1, 2006, 4.
113. [113] Li, Y., Jiang, L., Jia, Z., Xin, W., Yang, S., Yang, Q., et al. A meta-analysis of red yeast rice: an effective and relatively safe alternative approach for dyslipidemia. PLoS One, 9, 2014, e98611.
114. [114] Gerards, M.C., Terlou, R.J., Yu, H., Koks, C.H., Gerdes, V.E., Traditional Chinese lipid-lowering agent red yeast rice results in significant LDL reduction but safety is uncertain - a systematic review and meta-analysis. Atherosclerosis 240 (2015), 415–423.
115. [115] Xiong, X., Wang, P., Li, X., Zhang, Y., Li, S., The effects of red yeast rice dietary supplement on blood pressure, lipid profile and C-reactive protein in hypertension: a systematic review. Crit Rev Food Sci Nutr, 2015 [Epub ahead of print].
116. [116] Halbert, S.C., French, B., Gordon, R.Y., Farrar, J.T., Schmitz, K., Morris, P.B., et al. Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance. Am J Cardiol 105 (2010), 198–204.
117. [117] Becker, D.J., Gordon, R.Y., Halbert, S.C., French, B., Morris, P.B., Rader, D.J., Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial. Ann Intern Med 150 (2009), 830–839.
118. [118] Lu, Z., Kou, W., Du, B., Wu, Y., Zhao, S., Brusco, O.A., et al., Chinese Coronary Secondary Prevention Study Group. Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. Am J Cardiol 101 (2008), 1689–1693.
119. [119] Zhao, S.P., Liu, L., Cheng, Y.C., Shishehbor, M.H., Liu, M.H., Peng, D.Q., et al. Xuezhikang, an extract of cholestin, protects endothelial function through antiinflammatory and lipid-lowering mechanisms in patients with coronary heart disease. Circulation 110 (2004), 915–920.
120. [120] Gordon, R.Y., Cooperman, T., Obermeyer, W., Becker, D.J., Marked variability of monacolin levels in commercial red yeast rice products. Arch Intern Med 170 (2010), 1722–1727.
121. [121] Heber, D., Lembertas, A., Lu, Q.Y., Bowerman, S., Go, V.L., An analysis of nine proprietary Chinese red yeast rice dietary supplements: implications of variability in chemical profile and contents. J Altern Complement Med 7 (2001), 133–139.
122. [122] Imanshahidi, M., Hosseinzadeh, H., Pharmacological and therapeutic effects of Berberis vulgaris and its active constituent, berberina. Phytother Res 22 (2008), 999–1012.
123. [123] Pirillo, A., Catapano, A.L., Berberine, a plant alkaloid with lipid- and glucose-lowering properties: from in vitro evidence to clinical studies. Atherosclerosis 243 (2015), 449–461.
124. [124] Lee, S., Lim, H.J., Park, J.H., Lee, K.S., Jang, Y., Park, H.Y., Berberine induced LDLR upregulation involves JNK pathway. Biochem Biophys Res Commun 362 (2007), 853–857.
125. [125] Kong, W., Wei, J., Abidi, P., Lin, M., Inaba, S., Li, C., et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med 10 (2004), 1344–1351.
126. [126] Cameron, J., Ranheim, T., Kulseth, M.A., Leren, T.P., Berge, K.E., Berberine decrease PCSK9 expression in HepG2 cells. Atherosclerosis 201 (2008), 266–273.
127. [127] Brusq, J.M., Ancellin, N., Grondin, P., Guillard, R., Martin, S., Saintillan, Y., et al. Inhibition of lipid synthesis through activation of AMP kinase: an additional mechanism for the hypolipidemic effects of berberine. J Lipid Res 47 (2006), 1281–2188.
128. [128] Dong, H., Wang, N., Zhao, L., Lu, F., Berberine in the treatment of type 2 diabetes mellitus: a systemic review and meta-analysis. Evid Based Complement Alternat Med, 2012, 2012, 591654.
129. [129] Dong, H., Zhao, Y., Zhao, L., Lu, F., The effects of berberine on blood lipids: a systemic review and meta-analysis of randomized controlled trials. Planta Med 79 (2013), 437–446.
130. [130] Lan, J., Zhao, Y., Dong, F., Yan, Z., Zheng, W., Fan, J., et al. Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. J Ethnopharmacol 161 (2015), 69–81.
131. [131] Kong, W.J., Wei, J., Zuo, Z.Y., Wang, Y.M., Song, D.Q., You, X.F., et al. Combination of simvastatin with berberine improves the lipid-lowering efficacy. Metabolism 57 (2008), 1029–1037.
132. [132] Guo, Y., Chen, Y., Tan, Z.R., Klaassen, C.D., Zhou, H.H., Repeated administration of berberine inhibits cytochromes P450 mRNA expression and activities in mice. J Ethnopharmacol 138 (2011), 111–118.
133. [133] Castellanos-Jankiewicz, A., Del Bosque-Plata, L., Tejero, M.E., Combined effect of plant sterols and dietary fiber for the treatment of hypercholesterolemia. Plant Foods Hum Nutr 69 (2014), 93–100.
134. [134] Clifton, P.M., Noakes, M., Sullivan, D., Erichsen, N., Ross, D., Annison, G., et al. Cholesterol-lowering effects of plant sterol esters differ in milk, yoghurt, bread and cereal. Eur J Clin Nutr 58 (2004), 503–509.
135. [135] Theuwissen, E., Mensink, R.P., Simultaneous intake of beta-glucan and plant stanol esters affects lipid metabolism in slightly hypercholesterolemic subjects. J Nutr 137 (2007), 583–588.
136. [136] Becker, D.J., French, B., Morris, P.B., Silvent, E., Gordon, R.Y., Phytosterols, red yeast rice, and lifestyle changes instead of statins: a randomized, double-blinded, placebo-controlled trial. Am Heart J 166 (2013), 187–196.
137. [137] Cicero, A.F., Rovati, L.C., Setnikar, I., Eulipidemic effects of berberine administered alone or in combination with other natural cholesterol-lowering agents. A single-blind clinical investigation. Arzneimittelforschung 57 (2007), 26–30.
138. [138] Affuso, F., Ruvolo, A., Micillo, F., Saccà, L., Fazio, S., Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelial function randomized, double-blind, placebo-controlled study. Nutr Metab Cardiovasc Dis 20 (2010), 656–661.
139. [139] Pirro, M., Lupattelli, G., Del Giorno, R., Schillaci, G., Berisha, S., Mannarino, M.R., et al. Nutraceutical combination (red yeast rice, berberine and policosanols) improves aortic stiffness in low-moderate risk hypercholesterolemic patients. Pharma Nutr 1 (2013), 73–77.
140. [140] Ruscica, M., Gomaraschi, M., Mombelli, G., Macchi, C., Bosisio, R., Pazzucconi, F., et al. Nutraceutical approach to moderate cardiometabolic risk: results of a randomized, double-blind and crossover study with armolipid plus. J Clin Lipidol 8 (2014), 61–68.
141. [141] Solà, R., Valls, R.M., Puzo, J., Calabuig, J.R., Brea, A., Pedret, A., et al. Effects of poly-bioactive compounds on lipid profile and body weight in a moderately hypercholesterolemic population with low cardiovascular disease risk: a multicenter randomized trial. PLoS One, 9, 2014, e101978.
142. [142] Gonnelli, S., Caffarelli, C., Stolakis, K., Cuda, C., Giordano, N., Nuti, R., Efficacy and tolerability of a nutraceutical combination (red yeast rice, policosanols, and berberine) in patients with low-moderate risk hypercholesterolemia: a double-blind, placebo-controlled study. Curr Ther Res Clin Exp 77 (2014), 1–6.
143. [143] Pisciotta, L., Bellocchio, A., Bertolini, S., Nutraceutical pill containing berberine versus ezetimibe on plasma lipid pattern in hypercholesterolemic subjects and its additive effect in patients with familial hypercholesterolemia on stable cholesterol-lowering treatment. Lipids Health Dis, 11, 2012, 123.
144. [144] Marazzi, G., Pelliccia, F., Campolongo, G., Quattrino, S., Cacciotti, L., Volterrani, M., et al. Usefulness of nutraceuticals (armolipid plus) versus ezetimibe and combination in statin-intolerant patients with dyslipidemia with coronary heart disease. Am J Cardiol 116 (2015), 1798–1801.
145. [145] Guardamagna, O., Abello, F., Baracco, V., Stasiowska, B., Martino, F., The treatment of hypercholesterolemic children: efficacy and safety of a combination of red yeast rice extract and policosanols. Nutr Metab Cardiovasc Dis 21 (2011), 424–429.
146. [146] Pirro, M., Mannarino, M.R., Bianconi, V., Simental-Mendía, L.E., Bagaglia, F., Mannarino, E., et al. The effects of a nutraceutical combination on plasma lipids and glucose: a systematic review and meta-analysis of randomized controlled trials. Pharmacol Res 110 (2016 May 6), 76–88.
147. [147] Pirro, M., Mannarino, M.R., Ministrini, S., Fallarino, F., Lupattelli, G., Bianconi, V., et al. Effects of a nutraceutical combination on lipids, inflammation and endothelial integrity in patients with subclinical inflammation: a randomized clinical trial. Sci Rep, 6, 2016 Mar 23, 23587.
148. [148] Alevizos, A., Mihas, C., Mariolis, A., Advertising campaigns of sterol-enriched food. An often neglected cause of reduced compliance to lipid lowering drug therapy. Cardiovasc Drugs Ther 21 (2007), 133–134.
149. [149] Eussen, S.R., de Jong, N., Rompelberg, C.J., Garssen, J., Verschuren, W.M., Klungel, O.H., Effects of the use of phytosterol/-stanol-enriched margarines on adherence to statin therapy. Pharmacoepidemiol Drug Saf 19 (2010), 1225–1232.
150. [150] European Food Safety Authority, A report from the data collection and exposure unit in response to a request from the European Commission. EFSA J 133 (2008), 1–21.
151. [151] Bonaccio, M., Bonanni, A.E., Di Castelnuovo, A., De Lucia, F., Donati, M.B., de Gaetano, G., et al., Moli-sani Project Investigators. Low income is associated with poor adherence to a Mediterranean diet and a higher prevalence of obesity: cross-sectional results from the Moli-sani study. BMJ Open, 2(6), 2012.
152. [152] Katsarou, A., Tyrovolas, S., Psaltopoulou, T., Zeimbekis, A., Tsakountakis, N., Bountziouka, V., et al. Socio-economic status, place of residence and dietary habits among the elderly: the Mediterranean islands study. Public Health Nutr 13 (2010), 1614–1621.
153. [153] Associazione Medici Diabetologi (AMD), Società Italiana di Diabetologia (SID), Standard italiani per la cura del diabete mellito. 2014.